Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EUGENIO ANGUEIRA-SERRANO

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1578621702
CMS profile
252541
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$52,798.25

311 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 7; records 51–100 of 311 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EUGENIO ANGUEIRA-SERRANO

NPI 1578621702 · CMS profile ID 252541

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 311 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578621702?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EUGENIO ANGUEIRA-SERRANO, NPI 1578621702, CMS profile ID 252541. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 311 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578621702?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EUGENIO ANGUEIRA-SERRANO, NPI 1578621702, CMS profile ID 252541. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 311 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578621702?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EUGENIO ANGUEIRA-SERRANO, NPI 1578621702, CMS profile ID 252541, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 311 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578621702?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

311 matching records · $52,798.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 311 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 311.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insulet Corporation $6.7510/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116820842 CMS
Insulet Corporation $0.8810/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116820844 CMS
Novo Nordisk Inc $17.7610/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097670514 CMS
Xeris Pharmaceuticals, Inc. $20.4110/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144594336 CMS
Lilly USA, LLC $121.8710/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136169191 CMS
Novo Nordisk Inc $750.0010/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097770678 CMS
Novo Nordisk Inc $24.1810/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096580305 CMS
ABBVIE INC. $8.3510/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228041 CMS
Alexion Pharmaceuticals, Inc. $20.2610/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093987882 CMS
Corcept Therapeutics $84.3810/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757897 CMS
AstraZeneca Pharmaceuticals LP $23.5710/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105412577 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.5910/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118066431 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.6810/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086231464 CMS
Dexcom, Inc. $19.6510/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153299587 CMS
Novo Nordisk Inc $938.0010/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097060499 CMS
Amphastar Pharmaceuticals, Inc. $21.8810/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149958228 CMS
Antares Pharma, Inc. $19.4310/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146447504 CMS
Corcept Therapeutics $50.0010/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757943 CMS
Corcept Therapeutics $9.2510/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757945 CMS
SANOFI-AVENTIS U.S. LLC $18.7810/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139635217 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $800.0009/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118066439 CMS
Corcept Therapeutics $772.9509/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757919 CMS
Lilly USA, LLC $19.8509/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134970231 CMS
Lilly USA, LLC $17.4209/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136169201 CMS
Abbott Laboratories $17.5709/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125134750 CMS
Tandem Diabetes Care, Inc. $36.4209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138747515 CMS
Corcept Therapeutics $7,950.0009/20/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757935 CMS
Corcept Therapeutics $301.9509/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757947 CMS
Corcept Therapeutics $265.5309/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757949 CMS
Corcept Therapeutics $350.0009/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757951 CMS
Corcept Therapeutics $46.6109/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757953 CMS
Corcept Therapeutics $45.8309/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757955 CMS
Corcept Therapeutics $81.8209/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757957 CMS
Lilly USA, LLC $19.0309/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134970087 CMS
Xeris Pharmaceuticals, Inc. $17.4109/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144594332 CMS
Novartis Pharmaceuticals Corporation $16.1209/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086726853 CMS
Insulet Corporation $114.6209/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116807825 CMS
Novo Nordisk Inc $23.3809/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097463985 CMS
Corcept Therapeutics $19.8809/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757877 CMS
Xeris Pharmaceuticals, Inc. $114.1309/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144594316 CMS
SANOFI-AVENTIS U.S. LLC $17.5909/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139635219 CMS
ABBVIE INC. $13.6609/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103228039 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.4009/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086163842 CMS
Corcept Therapeutics $3,000.0009/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757895 CMS
Corcept Therapeutics $2,500.0009/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757909 CMS
Insulet Corporation $4.4309/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116807827 CMS
Medtronic, Inc. $19.0109/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119384224 CMS
Corcept Therapeutics $25.0008/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757907 CMS
Corcept Therapeutics $100.0008/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757899 CMS
Corcept Therapeutics $275.0008/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117757901 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $132,183.35 381
PY2020 $61,795.88 282
PY2021 $114,420.29 385
PY2022 $80,230.48 337
PY2023 $51,003.70 304
PY2024 $52,798.25 311
PY2025 $110,468.72 356

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $503,679.43 205
PY2024 Principal investigator $304,621.01 150
PY2023 Principal investigator $401,391.13 341
PY2022 Principal investigator $318,849.98 897
PY2019 Principal investigator $103,153.43 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

205 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,152.00 12/31/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,407.60 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $133.63 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.70 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.70 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.30 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $133.63 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $156.00 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $156.00 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 12/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.70 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $133.63 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.70 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $133.63 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $133.63 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.70 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.30 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.70 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $133.63 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,644.40 12/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274749
Principal investigator 1 ABBVIE INC. $16,645.50 12/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,518.10 12/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184269393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/20/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184263283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 11/20/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184263285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,253.00 11/20/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $74.25 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184260907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.49 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184260909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.49 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184260911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338.84 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184260913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.30 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184260915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $74.25 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184260917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.49 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338.84 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $74.25 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338.84 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.30 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.49 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.49 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $74.25 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338.84 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.30 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338.84 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.30 11/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184259187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 11/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184259189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,695.00 11/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184259191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184259193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 11/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184259195
Principal investigator 1 ABBVIE INC. $52,658.10 11/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.00 10/29/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184253748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,200.00 10/29/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184253750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,764.00 10/16/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 10/16/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.62 10/16/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 10/16/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 10/16/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.74 10/16/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.93 10/16/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250819
Principal investigator 1 ABBVIE INC. $21,193.65 10/09/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515091
Principal investigator 1 ABBVIE INC. $169.22 10/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,884.50 10/03/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244789
Principal investigator 1 ABBVIE INC. $205.00 09/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $205.16 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $263.22 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $311.79 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.74 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.93 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.74 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.93 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.00 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 09/12/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236672
Principal investigator 1 ABBVIE INC. $20,769.75 09/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509376
Principal investigator 1 ABBVIE INC. $7,887.00 09/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 09/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184235273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.65 09/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184235275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 09/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184235277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $336.15 09/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184235279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $156.60 09/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184235281
Principal investigator 1 ABBVIE INC. $5,000.00 09/03/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202507845
Principal investigator 1 ABBVIE INC. $280.48 08/28/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202506469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 08/26/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184230453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $259.16 08/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184228381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,295.27 08/14/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184228383
Principal investigator 1 ABBVIE INC. $15,982.65 08/06/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,702.55 07/17/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184217216
Principal investigator 1 ABBVIE INC. $25,500.15 07/02/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 06/24/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184210710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 06/24/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184210712
Principal investigator 1 ABBVIE INC. $336.15 06/17/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202491723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184204281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $231.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184204283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184204285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184204287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,695.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184204289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184204291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184204293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.00 06/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204295
Principal investigator 1 ABBVIE INC. $37,091.25 06/03/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487777
Principal investigator 1 ABBVIE INC. $665.53 05/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487121
Principal investigator 1 ABBVIE INC. $21,089.70 05/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482701
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480529
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480531
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480533
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480535
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480545
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480551
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480553
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480555
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480557
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480559
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480561
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480563
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480565
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480569
Principal investigator 1 ABBVIE INC. $2,108.48 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480571
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480575
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480577
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480579
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480581
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480583
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480611
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480613
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480615
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480617
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480621
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480623
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480625
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480627
Principal investigator 1 ABBVIE INC. $95.84 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480629
Principal investigator 1 ABBVIE INC. $124.18 04/30/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,137.30 04/28/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184190611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.00 04/15/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184183198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,960.00 04/15/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184183200
Principal investigator 1 ABBVIE INC. $10,362.60 04/03/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471273
Principal investigator 1 ABBVIE INC. $7,887.00 03/26/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202466168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 03/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184174448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 03/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184174450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,695.00 03/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184174452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 03/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184174454
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 03/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184174456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $141.75 03/19/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184174458
Principal investigator 1 ABBVIE INC. $25,710.75 03/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,184.30 03/04/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156652
Principal investigator 1 ABBVIE INC. $95.84 02/26/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202454102
Principal investigator 1 ABBVIE INC. $124.18 02/26/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202454105
Principal investigator 1 ABBVIE INC. $124.18 02/25/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202453861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,445.05 02/25/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184155478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 02/18/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184154344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,695.00 02/18/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184154346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 02/18/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184154348
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 02/18/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184154350
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 02/18/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184154352
Principal investigator 1 ABBVIE INC. $284.00 02/13/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202451508
Principal investigator 1 ABBVIE INC. $680.38 02/13/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202451512
Principal investigator 1 ABBVIE INC. $124.18 02/13/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202451517
Principal investigator 1 ABBVIE INC. $124.18 02/11/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202450535
Principal investigator 1 ABBVIE INC. $124.18 02/06/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449274
Principal investigator 1 ABBVIE INC. $124.18 02/06/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449277
Principal investigator 1 ABBVIE INC. $124.18 02/06/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449488
Principal investigator 1 ABBVIE INC. $124.18 02/06/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449564
Principal investigator 1 ABBVIE INC. $33,636.60 02/06/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449568
Principal investigator 1 ABBVIE INC. $124.18 02/06/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,564.85 02/05/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184152504
Principal investigator 1 ABBVIE INC. $124.18 01/28/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202441687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,695.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $386.25 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $336.15 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,695.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 01/21/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,421.20 01/17/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184148197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,644.40 01/17/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,328.60 01/17/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,137.30 01/07/2025 Non-covered Recipient Entity
MED RESEARCH OF FLORIDA LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184145966